Lymphocryptoviruses such as Epstein-Barr virus (EBV) cause persistent infections in human and nonhuman primates, and suppression of the immune system can increase the risk of lymphocryptovirus (LCV)-associated tumor development in both human and non-human primates. To enable LCV infection as a non-clinical model to study effects of therapeutics on EBV immunity, we determined the genomic DNA sequence of the LCV from cynomolgus macaque, a species commonly used for non-clinical testing.
Introduction
Lymphocryptovirus (LCV) comprises a genus of doublestranded DNA gammaherpesviruses that cause lifelong infection in their respective primate hosts. The LCV that infects humans, Epstein-Barr virus (EBV), is recognized as a pathogen associated with several diseases, including infectious mononucleosis (IM), nasopharyngeal carcinoma, and lymphomas (Hislop et al., 2007; Okano and Gross, 2012; Thorley-Lawson and Gross, 2004) . The LCV in each primate species has likely co-evolved with that species, yet LCV from different primates are grossly similar (Veovodin and Marx, 2009) . LCV from the rhesus macaque (Macaca mulatta, an Old World primate), the most extensively studied non-human primate LCV, appears to be nearly identical to EBV in terms of tissue tropism and pathogenesis (Veovodin and Marx, 2009; Moghaddam et al., 1997; Rivailler et al., 2004; Wang et al., 2001) . Consistent with these similarities in biology, rhesus LCV and EBV share similar genomes: they have an identical genomic arrangement, all ORFs are present in both viruses, and a high degree of sequence similarity exists across a large number of genes (Rivailler et al., 2002a) . In particular, most rhesus LCV genes encoding structural proteins and proteins involved in viral replication are well conserved, whereas those encoding proteins involved in maintaining viral latency, cellular transformation, or immune evasion are more divergent (Rivailler et al., 2002b; Fogg et al., 2005; Jiang et al., 2000; Ohashi et al., 2012; Peng et al., 2000; Rivailler et al., 2002; Tellam et al., 2007) .
The genetic organization of LCV from the marmoset (Callithrix jacchus, a New World primate) is also similar to EBV, although there are some differences in genetic repertoire (Rivailler et al., 2002) . While there is sequence information available for individual LCV genes from other non-human primate species, complete genomic sequences are not available for the LCV from non-human primates besides the rhesus macaque and the marmoset. Because of the host species specificity of LCVs, phylogenetic relationships between different LCVs may mirror those between the host species, although this is not absolute (Ehlers et al., 2003; Ehlers et al., 2010; Lacoste et al., 2010) .
Although EBV infection is associated with IM, lymphomas, and other diseases, infection is asymptomatic in the vast majority of healthy individuals. The risk of developing EBV-related disease is greatly increased with immunosuppression, and transplant patients receiving immunosuppressive drugs as well as HIV/AIDS patients have increased EBV-associated lymphoproliferative disease or lymphomas (Clarke et al., 2013; Engels et al., 2008 Engels et al., , 2011 .
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In macaques as well, immunosuppression can lead to LCVassociated lymphoproliferative disorders (Rivailler et al., 2004; Kahnt et al., 2002; Marr-Belvin et al., 2008; Page et al., 2013; Schmidtko et al., 2002) .
Therapeutic immune suppression is intended for transplant or autoimmune indications, and many therapeutics may increase the risk of EBV-related disease, yet there are limited tools to evaluate effects on LCV immunity non-clinically. The cynomolgus macaque (Macaca fascicularis) is the non-human primate species most commonly used for non-clinical drug testing, and for biologics it is often the only species that shows cross-reactivity. LCV infection of cynomolgus monkeys is being explored as a non-clinical model to assess the potential for therapeutics to increase EBV-related disease (Kamperschroer et al., , 2014a (Kamperschroer et al., , 2014b Kawabata et al., 2012) ; however, current tools for using this model are immature. The genomic sequence of cynomolgus LCV has been suggested as a key piece of information needed to further develop the model (Kawabata et al., 2012) .
To allow for the development of additional tools to detect LCV (e.g. LCV-specific ISH probes, PCR primers/probes, or antibodies) as well as LCV-specific immune responses (e.g. immunogenic peptides/proteins and multimers for detecting LCV-specific T cells), we have sequenced the putative LCV genome from cynomolgus macaque (for simplicity, referred to in this report as cynomolgus LCV). Specifically, we sequenced LCV from cynomolgus macaque from the island of Mauritius because animals from this location are often used for non-clinical testing, and because this population may be particularly useful for evaluating antiviral immune responses (T cell responses) due to its restricted MHC diversity (Budde et al., 2010; Burwitz et al., 2009; Krebs et al., 2005; O'Connor et al., 2007 O'Connor et al., , 2010 . The resulting sequence information should facilitate basic research on lymphocryptoviruses as well as aid the development of cynomolgus LCV as a model of EBV in the setting of drug development.
Results
To determine the genomic sequence of cynomolgus macaque LCV, DNA was isolated directly from a lymphoblastic cell line (LCL) known to be infected with LCV (Kamperschroer et al., 2014) . In addition, the LCV genome from the LCL cells was enriched using pulse-field gel electrophoresis (PFGE) and subsequent isolation of the band (at an apparent size of 150 kb) corresponding to the putative LCV genomic DNA (Fig. 1A) . This enrichment resulted in approximately 50-fold higher abundance of LCV genome (lower C t values) as measured by a quantitative PCR assay specific for the BALF2 gene of cynomolgus LCV (Kamperschroer et al., 2014) , whereas the RPL13-A gene from the host cell line decreased in abundance following enrichment (Fig. 1B) . These two DNA templates were then used for next generation sequencing (NGS) to determine the cynomolgus LCV genomic DNA sequence.
Of the 16,106,748 paired-end reads from the unenriched LCL NGS sample, a total of 189, 088 (0.59%) reads mapped to the LCV genome for an average coverage of 113X. The NGS analysis of the enriched LCV sample had 11,816,996 paired-end reads of which 2,853,785 reads (12.1%) mapped to LCV, with an average coverage of 1704X. With both the unenriched and the enriched samples, coverage was fairly regular across the genome (see Supplementary  Fig. S1 ). Of note, however, there was an overabundance of coverage in the region around the internal repeat (IR) region 1, or IR1, consistent with there being multiple sequence repeats in this region. From the differences in percent LCV mapped reads, the LCV enrichment was calculated to be 22-fold, further supporting the quantitative PCR data indicating substantial enrichment of the viral DNA.
The resulting assembled genome of LCV from cynomolgus macaque is 154,158 bp. The genomic arrangement (shown in Fig. 2 ) is nearly identical to LCV from rhesus macaque as well as to EBV ( Fig. 2 and Rivailler et al. (2002) ). A comparison of the assembled cynomolgus LCV genome to all other viral whole genomes at NCBI revealed that the cynomolgus LCV genome is most Fig. 1 . Preparation of LCV genomic DNA for sequencing. (A) Isolation of LCV DNA using pulse-field gel electrophoresis (PFGE). High molecular weight DNA was isolated from LCV-transformed LCL, embedded in agarose, and subjected to PFGE. The discrete band migrating at approximately 150 kb (boxed) was excised and purified by β-agarase digestion. (B) Determination of LCV DNA enrichment. The relative copy number of LCV genome in unenriched and PFGE-enriched (as in A) DNA samples was determined using a quantitative PCR assay specific for the BALF2 gene of cynomolgus LCV and for the cellular endogenous control gene, RPL13A. Amplification plots for BALF2 and RPL13A are shown. The BALF2 (LCV specific) C t values for the duplicate unenriched LCL DNA samples were 17.00 and 17.18, and the C t values for the LCV-enriched DNA samples were 15.44 and 15.63. The C t values for the RPL13A endogenous cellular control gene were 22.7 and 22.9 for the duplicate unenriched samples and 26.91 and 26.94 for the enriched LCV samples. Fig. 2 . Genomic arrangement of LCV from cynomolgus macaque. Blue and green arrows indicate protein coding genes on the plus and minus strands, respectively. Light blue arrows show the non-coding mRNA EBER1 and EBER2 genes as well as a genomic region encoding genes for which the precise protein coding regions have not been defined by sequence similarity. Light gray bars indicate repeat regions, for which the precise number of repeats is undefined. similar to lymphocryptoviruses (data not shown). When the cynomolgus LCV genome is compared to other whole LCV genomes, rhesus LCV (Macacine herpesvirus 4) is identified as closest relative (Fig. 3A) . Alignment of cynomolgus LCV to rhesus LCV shows a high degree of similarity between the two sequences over the majority of the genomes (Fig. 3B) . However, there do appear to be regions of dissimilarity near the right end of the genome, most notably at approximately 123-133 kbp and 149-153 kbp. The former region contains the repetitive region IR4 and a block of sequence with no protein coding sequences (CDS). Since no proteins are encoded here, this region may have diverged at a higher rate than the rest of the genome. This region is also flanked by LF3 (Fig. 2) , which exhibits low sequence similarity between viral species (Rivailler et al., 2002) . The latter region at approximately 149-153 kbp does not contain any proteins and may also have diverged to a greater extent.
Although the sequence was generally consistent across different reads, there was heterogeneity observed at a number of nucleotide positions, suggesting the presence of at least one viral variant (Supplementary Table S1 ). Although the nucleotide differences were not assigned to specific variants, there were predominantly two populations of nucleotides at a given position, suggesting two predominant variants. The heterogeneity did show selectivity for specific genes. Specifically, it was observed in multiple EBNA genes, and was more prevalent (i.e., at multiple nucleotide positions) in EBNA-3C, BOLF1, BFRF2, EBNA-1, and the predicted EBNA-LP gene.
Similar to LCV from other species, there were several repeat regions present in the cynomolgus LCV genome. The internal repeats IR2 and IR4 (OriLyt) mapped from nucleotide positions 23,758 to 25,258 and 124,958 to 126,458 respectively. The IR3 mapped between 79,608 and 80,158 and contained an overrepresentation of G residues, resulting in discontinuous repetitive features when aligned to itself. While there were only short ( 100 bp) repeats at the right end of the cynomolgus LCV genome sequence, the best similarity with the last 1000 bp this region was to the last 1000 bp of the rhesus LCV genome (81% identity). Similarly, the first 2500 bp of the cynomolgus LCV genome showed highest similarity to the first 2500 bp of the rhesus LCV genome (78% identity). Based on this similarity we assigned these regions as the start and end of the cynomolgus LCV genome. The largest repeat region maps to residues 11,953 to 20,006 and corresponds to the large W repeat region (IR1) previously reported in the rhesus LCV (NC_006146.1) and marmoset LCV (NC_004367.1) genomes (Rivailler et al., 2002; Rivailler et al., 2002) . Because the size of this repeat region and the arrangement of the repeats was difficult to determine using the NGS data, multiple high fidelity "long" PCR products spanning the IR1 region were generated using different primer sets, their approximate sizes were determined by gel electrophoresis, and they were cloned and sequenced using PacBio. Based on the initial NGS data as well as the PacBio sequencing of the PCR products, there are 2.7 repeats of a 3000 nucleotide sequence in IR1 of cynomolgus LCV, which shows high similarity to the IR1 repeat sequence of rhesus LCV. This number of repeats in the cynomolgus LCV IR1 is lower than the 5.7 repeats reported for rhesus LCV IR1 and the 11.3 repeats reported for IR1 from the B95-8 isolate of EBV (Rivailler et al., 2002) . The terminal repeat (TR) region in rhesus LCV has 4 repeats (Rivailler et al., 2002) whereas NGS of cynomolgus LCV identifies a single repeat. The difference in the TR region may represent technical limitations of NGS of repetitive regions (Treangen and Salzberg, 2012) , rather than a true difference between the different species of LCV.
Based on sequence and positional similarity to ORFs in other LCV species as well as Sanger-based sequencing of cloned cDNA products, 76 open reading frames were identified in the cynomolgus LCV genome. Global alignments of encoded proteins to proteins from LCV in the common marmoset (Callitrichine herpesvirus 3; NC_004367.1 ), EBV (Human herpesvirus 4 type 2; NC_009334.1), and the rhesus macaque (Macacine herpesvirus 4; NC_006146.1) revealed protein similarities ranging from 99.7% identity to essentially no (3.6%) identity (Fig. 2, Table 1 , and Supplementary Table S2 ). In general, a high degree of similarity was observed in lytic phase structural proteins or DNA replication proteins; as examples, BALF5, BBLF4, BDLF1, and BcLF1 showed 98-99% identity with rhesus LCV and 93-97% identity with EBV. Latency proteins such as those encoded by the EBNA genes showed lower similarity; EBNA-1, EBNA-2, and EBNA-3A-C showed 70-89% identity with rhesus LCV and 33-44% identity with EBV (Table 1) . Immunomodulatory proteins might be expected to also have lower similarity and this was observed in some genes; however, the colony stimulating factor (CSF)-1 receptor homolog BARF1 had a very high degree of similarity, showing 99.7% identity with rhesus LCV and 96% identity with EBV (Table 1) . Similarity of cynomolgus LCV would be expected to be higher with rhesus LCV than with EBV, given the evolutionary relationships between the hosts. This was true in most cases, but some proteins showed greater similarity to EBV than to rhesus LCV. As examples, BcRF1, a protein of unknown function, showed 72% identity with rhesus LCV and 82% identity with EBV, and the uncharacterized protein The cynomolgus LCV genome sequence was compared to all available lymphocryptovirus whole genome sequences, and a similarity tree was generated from resulting alignments. Aligning sequences were: Callitrichine herpesvirus 3 (NC_004367.1), Human herpesvirus 4 (NC_007605.1), Human herpesvirus 4 type 2 (NC_009334.1), and Macacine herpes virus 4 (NC_006146.1). (B) The cynomolgus LCV genome was aligned to the rhesus LCV genome (Macacine herpesvirus 4, NC_006146) using MEGABLAST. BNLF2b showed 65% identity with rhesus LCV and 71% identity with EBV (Table 1) .
Determination of the precise intron/exon boundaries and therefore the predicted protein sequences for two latency proteins, EBNA-LP and LMP1, was precluded by the difficulty of NGS sequencing through repetitive regions (Treangen and Salzberg, 2012) , the low similarity with related species, the presence of multiple exons in these genes, and the inability to generate and clone cDNA products for these genes. However, these genes were present within the genomic DNA sequence, as evidenced by similarity to the corresponding rhesus LCV genes in the same genomic locations (data not shown). A homolog of BARF0, a CTL target for EBV (Kienzle et al., 1998) , was not identified in cynomolgus LCV. Interestingly, there is a region in the cynomolgus LCV genome at position 143,329 to 143,811 which could encode a BARF0 with 95% identity to the rhesus LCV BARF0; however, this putative cynomolgus LCV BARF0 gene has a stop codon after amino acid residue 10, suggesting that the gene encodes a truncated protein.
In the cynomolgus LCV, the BBLF2/BBLF3 protein is synthesized as a single polypeptide. This fusion is unlike the state reported for rhesus LCV (Rivailler et al., 2002) , but it has been reported in other LCVs, including EBV (Dolan et al., 2006) . It is not known whether this is a true difference between the rhesus LCV and cynomolgus LCV genomes or whether the reported rhesus LCV BBLF2/BBLF3 proteins are actually synthesized as a single protein.
Recently Skalsky et al. reported that, like EBV, rhesus LCV expresses more than 30 microRNAs (miRNAs) (Skalsky et al., 2014) . We used the precursor miRNA sequences from this virus as listed at miRBase to search for homologs within the cynomolgus LCV genome. Of the 36 sequences examined, we found regions of greater that 95% identity to rlcv-mir-rL1-1, rlcv-mir-rL1-2, rlcvmir-rL1-17, & rlcv-mir-rL1-18 (data not shown). No other regions with greater that 70% identity were found. Further investigation is required to determine if these four candidate miRNAs or other miRNAs are expressed.
Discussion
To our knowledge, the results presented here represent the first reporting of the sequence of the LCV genome from cynomolgus macaques. Overall, there was a high degree of similarity observed between cynomolgus LCV and rhesus LCV (and to a lesser extent, EBV), as would be expected given the close evolutionary relationship between the hosts. It was also expected that latency proteins or immune evasion proteins would show less similarity (Rivailler et al., 2002; Rivailler et al., 2002) , and this was also true in most cases. However, the CSF-1 receptor protein encoded by BARF1 showed very high similarity with both rhesus LCV and EBV. BARF1 is a homolog of the colony stimulating factor (CSF)-1 receptor that can block CSF-1 signaling. It may promote B cell transformation in rhesus monkeys, but is not required for viral replication or for B cell transformation (Ohashi et al., 2012) . Also, while BARF1 is a CTL target in humans (Martorelli et al., 2008) and therefore may be under immune pressure, BARF1 has not been identified as a CTL target in rhesus monkeys (Orlova et al., 2011) . Given these observations, the high degree of similarity of BARF1 is surprising and merits further investigation. Some cynomolgus LCV proteins, such as BcRF1 and BNLF2b, displayed higher similarity to EBV than they did to rhesus LCV, suggesting the possibility that these genes underwent selection driven by factors other than host evolution. However, this observation could also relate to differences between LCV in cynomolgus macaques and rhesus macaques, or properties of the population of cynomolgus macaques from Mauritius, which could result from founder selection, differences in pathogen-driven selective pressure, or other factors. Particularly for the immune evasion genes and the latency genes involved in B cell transformation, it will be of interest to determine how LCV from cynomolgus macaques from different geographic locations compare to each other and to other primate species.
Based on the sequence reported here, the cynomolgus LCV BARF0 gene encodes a truncated protein due to a stop codon after amino acid residue 10. BARF0 is a target for cytotoxic T-cells against Epstein-Barr virus (EBV) (Kienzle et al., 1998 ), yet it does not appear to be critical for EBV replication or B cell transformation (Wilkie et al., 2014) . Although changes acquired during long term culture of the virus are possible, it is also possible that selective pressure and/or species isolation has resulted in the early truncation of this protein in the Mauritian cynomolgus LCV we have sequenced. Such truncation of genes or gene products has been observed in other lymphocryptoviruses and in other herpesviruses in other species, and may represent changes fixed by selective pressure (Wilkie et al., 2014; Aoki et al., 2007; Cheung et al., 1998) .
The IR1 of EBV, rhesus LCV (Rivailler et al., 2002) , and cynomolgus LCV (this report) contains coding sequences for EBNA-2 and EBNA-LP, and the number of repeats has been shown to correlate with efficiency of transformation (Tierney et al., 2011) . The IR1 from our cynomolgus LCV sequence contains 2.7 major repeats, which is different from the 5.7 repeats reported for the IR1 of rhesus LCV. The number of IR1 repeats in different EBV isolates or even different cell lines derived from the same donor can be highly variable (Tierney et al., 2011; Allan and Rowe, 1989) , so differences in repeat numbers are not unexpected. The impact of IR1 repeat number on viral transformation with cynomolgus LCV has not been determined, but inference from EBV would predict an IR1 repeat number of 2.7 to be suboptimal for inducing transformation (Tierney et al., 2011) .
Our primary goal for sequencing the cynomolgus LCV was to enable the development of tools to monitor both LCV as well as immune responses against LCV in the cynomolgus macaque in the setting of drug development. Past efforts to develop such tools have been hampered in some cases by a lack of knowledge of gene or protein sequences. For example, we have generated overlapping peptide pools based on rhesus LCV sequences in order to detect T cell responses against cynomolgus LCV proteins (eg. EBNA-1, EBNA-3A-C, LMP1, BZLF1), but were unable to detect T cell responses (L.O. and C.K., unpublished observations). The lack of responses for at least some of the proteins may have been due to sequence differences in the synthesized peptides compared to the bona fide cynomolgus LCV sequences, particularly for proteins with greater divergence. Cynomolgus LCV sequence will circumvent these complications and will allow the generation of a number of tools, including quantitative PCR or ISH assays to detect virus or viral gene expression, peptides for stimulating T cell responses, and peptide-MHC multimers for detecting Ag-specific T cells. The LCV sequence from Mauritian cynomolgus macaques may be particularly valuable for studying anti-LCV T cell immunity due to the highly restricted MHC diversity in that population (Budde et al., 2010; Burwitz et al., 2009; Krebs et al., 2005; O'Connor et al., 2007 O'Connor et al., , 2010 . The small number of MHC haplotypes in the Mauritian population may enable the selection of a relatively small number of immunogenic peptides that are able to selectively stimulate either CD4 T cell or CD8 T cell responses in most, if not all, individual animals, without the need for MHC haplotyping and selection of animals. Once immunogenic peptides are defined, multimers for direct staining of LCV-specific T cells can also be generated, and a small pool of multimers may allow for detection of responses in all animals. The ability to measure LCVspecific T cell responses may also have broader utility beyond evaluating the potential for EBV-related disease, in that LCVspecific T cell responses could be used in a general way to directly monitor effects of therapeutics on cell mediated immunity in monkeys.
Methods for detecting the LCV genome, measuring LCV gene expression, and evaluating immunity to LCV will allow for the further development of LCV infection in cynomolgus macaques as a non-clinical model for EBV in humans. This model is currently being explored as a way to evaluate the risk that a candidate therapeutic will impact immunity against LCV and increase the risk of EBV-related disease in humans Kamperschroer et al., 2014; Kamperschroer et al., 2014; Kawabata et al., 2012) . The genomic sequence of LCV from the cynomolgus macaque will greatly facilitate these efforts.
Materials and methods

LCL generation
Mauritius-origin adult cynomolgus macaques (Macaca fascicularis), obtained from Charles River Laboratories (Houston, TX) and housed at Pfizer in Groton, CT were used for all experiments. Housing and all procedures were conducted in accordance with the guidelines of the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Peripheral blood mononuclear cells (PBMC) were used to generate an LCVtransformed lymphoblastic cell line (LCL), as previously described (Kamperschroer et al., 2014) . Briefly, PBMCs were isolated from a healthy three-year-old female monkey and cultured at 10 6 cells/mL in flat bottomed 96-well plates (Costar) for approximately 3 weeks in complete media comprised of RPMI 1640 medium supplemented with 10% FBS, 2 mM Glutamax, penicillin/ streptomycin/amphotericin B, 0.1 mM non-essential amino acids, and 1 mM sodium pyruvate (all from Invitrogen). Cells were then cultured for approximately 12 weeks in the presence of complete media containing 2 ug/mL cyclosporine to prevent immune cell control over LCV-infected B cells. The LCL surviving at the end of this culture period was characterized to confirm the presence of LCV (Kamperschroer et al., 2014) and cryopreserved. After thawing, the LCL was cultured for 3 weeks in complete media and then DNA was isolated from the LCL for sequencing.
DNA extraction and isolation
High molecular weight genomic DNA for sequencing was isolated directly from a cynomolgus monkey LCV-transformed LCL using Qiagen's genomic tip and genomic DNA buffer set (Qiagen Inc. Valencia, CA) according to the manufacturer's protocol. In addition, pulse-field gel electrophoresis (PFGE) of agaroseembedded DNA samples was performed using the CHEF-DR III PFGE system (Bio-Rad Laboratories Hercules, CA) at 6 V/cm at 14°C. Switch time was ramped from 50 to 90 s for 19 h. Following band visualization with ethidium bromide, the discrete band migrating at approximately 150 kb was excised and purified by β-agarase digestion ( New England BioLabs Inc., Ipswich, MA) followed by isopropanol precipitation.
Quantitative PCR
Real time PCR assays for detection of cynomolgus monkey LCV (BALF2) genomic DNA as well as for the cellular endogenous control gene RPL13A.R.A. (RPL13A, used for normalization) were performed as described previously (Kamperschroer et al., 2014) . Briefly, unenriched and PFGE-enriched DNA samples isolated from a cynomolgus monkey LCV-transformed B cell line (see DNA extraction and isolation section above) were run in duplicate on the ABI 7900HT Real Time PCR system with SDS v2.4 Enterprise data acquisition software (ABI). Samples were analyzed using RQ Manager software (ABI) and were normalized to their endogenous controls, and all samples were compared to the unenriched genomic DNA calibrator sample.
Whole-genome sequencing
Cynomolgus monkey LCV DNA samples were submitted for whole genome sequencing to BGI (Hong Kong). A custom low template input library preparation and a combination of standard Illumina and in-house protocols were used to produce multiplexed paired-end libraries of extracted DNA with an average insert size of 200 bp. Sequencing was performed on the Illumina HiSeq 2000, generating 100 bp paired-end reads. For the unenriched DNA sample, a set of fastq reads were generated using the SOAP alignment tool that consisted of all those reads which were not similar to the cynomolgus monkey genome (GCA_000222185.1). This set of filtered reads and the set of unfiltered reads from the enriched LCV DNA sample were used for virus genome assembly.
Sequence analyses
Initial sequence assembly was performed by aligning the direct/filtered sample reads to rhesus macaque LCV (Macacine herpesvirus 4; NC_006146.1) using bwa (Skalsky et al., 2014) . A consensus sequence was generated using samtools (Garcia-Alcalde et al., 2012) . The direct/filtered reads were also assembled using the de novo assembly tool Abyss (Cheung et al., 1998) . De novo assembly sequences generated by Abyss were aligned to the consensus sequence using BLAST (Orlova et al., 2011) . Alignments were used to manually fill-in mismatches and gaps. Further manual annotation was performed after bwa alignment with the enriched virus sample reads and BLAST alignment with Abyss assembled enriched virus sample sequences. Coverage calculations and visualizations were generated using Qualimap (Garcia-Alcalde et al., 2012) . All visualizations of read sequences to the generated cynomolgus macaque LCV genome were performed using the Integrated Genome Viewer from the Broad Institute (Aoki et al., 2007) . Single exon ORFs were identified from the ORFs generated from a six-frame translation of the viral genome with the highest BLAST similarity to rhesus macaque LCV (Macacine herpesvirus 4) proteins. Additional multi-exon ORFs were identified by aligning protein and mRNA sequences from the rhesus LCV genome to the completed cynomolgus virus genome. Final visualization of the genome and protein coding sequences was perfomed using gview (Allan and Rowe, 1989) . Global sequence alignments between cynomolgus LCV proteins and other herpesvirus protein was performed using the EMBOSS tool 'stretcher' (Tierney et al., 2011) . Inter-viral genome comparisons were performed using blastn at the NCBI website (http://blast.ncbi.nlm.nih.gov/Blast.cgi) using the "Reference genomic sequences (refseq_genomic)" database while limiting the organisms to lymphocrytovirus (txid:10375).
High fidelity PCR for IR1 sequence determination
Multiple primers flanking the IR1 region were designed and used in conjunction with the Long Amp High Fidelity PCR system (New England Biolabs, or NEB) to amplify multiple PCR products from genomic DNA isolated from the LCL infected with LCV. A final DMSO concentration of 2% allowed for amplification of the approximately 8.6 kb IR1 region. Multiple PCR products were pooled and then cloned using the NEB PCR cloning kit (NEB). Plasmid containing the 8.6 kb IR1 insert was then used for PacBio sequencing (by Expression Analysis and BGI Hong Kong). The resulting sequence was filtered for cloning vector.
Cloning and sequencing to determine protein coding sequences not determined by NGS Cynomolgus macaque LCL cDNA and the Long Amp PCR system containing a final DMSO concentration of 2% was used for amplification with specific primers for cynomolgus LCV EBNA-2, EBNA-LP, LMP1, LMP2A & LMP2B cDNA sequence. The resulting PCR products were cloned via the NEB PCR Cloning Kit (NEB) and then subjected to Sanger sequencing (by Genewiz).
Sequence accession number
The genomic sequence of LCV from cynomolgus macaque reported here can be accessed at accession number KP676001.
